Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Tirzepatide is a once-weekly subcutaneous injectable peptide (approved by the Food and Drug Administration [FDA] for type 2 diabetes) engineered from the native GIP sequence, with agonist activity at both the GIP and GLP-1 receptors
No, Mounjaro is one of the brand names for tirzepatide
These findings reinforce the role of GLP-1RAs, and semaglutide in particular, as an important therapeutic option for patients with type 2 diabetes and established cardiovascular disease, supporting their inclusion in evidence-based guideline recommendations
What might change is the storage requirements and concentration of your vial, but those are reconstitution and dosing considerations, not pharmacokinetic ones
US$ 25.49
US$ 22.81
US$ 28.81
US$ 22.25
